Navigation Links
Vasogen Announces Sale of Patent Application and Provides Corporate Update
Date:2/2/2009

MISSISSAUGA, ON, Feb. 2 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN; TSX:VAS) today announced that it has sold a United States patent application and its related foreign counterparts for US$400,000. This device-based intellectual property has not been used to date in the Celacade System; however, Vasogen has retained rights to this technology for any potential use as it relates to its Celacade System.

The Company today also announced that it continues to advance the process associated with its ongoing strategic review and expects to be in a position to provide a further update to shareholders over the coming weeks. As previously announced, Vasogen has been reviewing various strategic alternatives for the purpose of enhancing shareholder value.

Certain statements in this document constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to complete a sale, merger, acquisition, or other strategic alternative, statements regarding the status of development, or expenditures relating to the Celacade(TM) System or our VP series of drugs including VP015 and VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements. You s
'/>"/>

SOURCE Vasogen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vasogen Complies with NASDAQ Marketplace Rule 4350(c)(1)
2. Vasogen Provides Corporate Update
3. Vasogen Announces Third Quarter 2008 Results
4. Vasogen Announces Second Quarter 2008 Results
5. Vasogen Provides Corporate Update
6. Vasogen to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price
8. Vasogen Announces Implementation of Strategic Restructuring Plan
9. Vasogen Announces First Quarter 2008 Results
10. Vasogen to Webcast its Annual Meeting
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)...  NuGene International, Inc. ("NuGene") (OTCQB: NUGN), announced ... has added another internationally recognized researcher to its ... internationally recognized researcher in bio-inspired materials and bio-materials ... University, China , Professor Guan ... North Carolina, Chapel Hill. Following a postdoctoral training ...
(Date:3/30/2015)... March 30, 2015    Intrexon Corporation ... biology, and Merck Serono, the biopharmaceutical business of ... today announced an exclusive strategic collaboration and license ... T-cell (CAR-T) cancer therapies. This collaboration advances Merck ... that modulate the immune system,s natural ability to ...
(Date:3/30/2015)... LONDON , March 30, 2015 ... Patienten auf    Richmond Pharmacology ist das ... Nationalen Amyloidose-Zentrum am Royal Free Hospital in ... Phase-3-Studie zur Untersuchung eines RNAi-Therapeutikums Studienversuche an einem ... Behandlung von Transthyretin vermittelter Amyloidose entwickelt (ATTR), einer ...
(Date:3/29/2015)... 2015 As a symbol of its ... our pharmaceutical manufacturing clients, Whitehouse Laboratories is excited to ... Berkenstock Race Team for the 2015 race season. Success ... but a strong sense of precision and attention to ... success in the quality control testing laboratory. Sponsorship of ...
Breaking Biology Technology:UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2
... Andrew Ryan Varian Australia Pty. Ltd., Mulgrave, 3170, Victoria, ... , The role of major, minor ... area of scientific research. In particular, research on the value of trace ... , The advent of atomic absorption ...
... Inc. , Introduction ... veterinary drugs. The use of these in food production is already ... the European Union because of a possible increased cancer-risk through long-term ... nitrofurans contamination has been found in warm-water prawns, shrimp, and chicken. ...
... in the yeast Saccharomyces cerevisiae : Detection in vivo using ... Paul Gavin# and Mark Prescott # , Ph.D , ... # Department of Biochemistry and Molecular Biology, Monash University, , ... * Technical assistance: Varian Australia Pty Ltd, Mulgrave, Victoria 3170, , ...
Cached Biology Technology:Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 2Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 3Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 4Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 5Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 6Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 7Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 8Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 9Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 10Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 11Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 12Analysis of Nitrofurans Metabolites by Positive Ion Electrospray LC/MS/MS 2Cytosolic expression of Green Fluorescent Protein (GFP) and its derivatives , in the yeast Saccharomyces cerevisiae: Detection in vivo using , the Varian Cary Eclipse 2Cytosolic expression of Green Fluorescent Protein (GFP) and its derivatives , in the yeast Saccharomyces cerevisiae: Detection in vivo using , the Varian Cary Eclipse 3Cytosolic expression of Green Fluorescent Protein (GFP) and its derivatives , in the yeast Saccharomyces cerevisiae: Detection in vivo using , the Varian Cary Eclipse 4Cytosolic expression of Green Fluorescent Protein (GFP) and its derivatives , in the yeast Saccharomyces cerevisiae: Detection in vivo using , the Varian Cary Eclipse 5
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, announces its biometric ... advertising campaign on CNBC television starting March 30 th ... commence airing in New York markets. ... said: "We are excited about our new ad campaign following ...
(Date:3/19/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... aired this week on Washington DC,s ... a segment "The Next Great Thing", host Laura Evans ... pay, and ,a really big breakthrough in mobile payment.,  ...
(Date:3/16/2015)... Between 16 and 20 ... innovations in biometric identification at the CeBIT exhibition ...      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ) , ... at the forefront: the company,s all new BiometricGate ... Germany . BiometricGate is the first ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... are on the verge of unleashing the power of the ... as decades of research begins to bear fruit. Boron has ... but is now attracting fast growing research interest and investment ... to tackle cancer and infectious diseases, potentially overcoming limitations and ...
... emissions is not the only threat to the planet. Changes ... widespread use of fertilizers, are also damaging both water quality ... Brush, from Johns Hopkins University in Baltimore, USA, in her ... large estuary on the Atlantic coast of the USA. Her ...
... has consisted in the development of class antagonismsthe exploitation ... Karl Marx and Frederick Engels, The Communist Manifesto ... group well being, it also may increase the potential ... control: which individuals gain the spoils and which toil ...
Cached Biology News:European researchers harness unique properties of boron to develop new drugs and diagnostics 2European researchers harness unique properties of boron to develop new drugs and diagnostics 3Fertilizers -- a growing threat to sea life 2Caste in the colony 2
Rab1A...
... LYZL6 ( Abpromise for all ... Synthetic peptide: DWLCL AFVE SKFNISKINE ... to amino acids 46-100 of Human ... ID: 57151 ...
Request Info...
Mouse monoclonal [DJR3] to DcR1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Biology Products: